taVNS for Chronic Kidney Disease
This study is looking at a treatment called transcutaneous auricular vagus nerve stimulation (taVNS) for people with chronic kidney disease (CKD) stages 3-5. taVNS uses a device similar to a TENS unit to stimulate a nerve in the ear. Researchers want to see if this treatment is safe, how well people can tolerate it, and if it helps with problems related to the body's automatic functions (autonomic nervous system dysfunction) in CKD. You might be able to join if you are 18 or older, have CKD stage 3-5, and receive care at NYU Nephrology. The study will measure how many people complete the treatment and how well they tolerate each session, as well as any serious side effects like a very slow heart rate. The study is currently unclear on its recruitment status.
- Study design
- This is an interventional study planning to enroll 30 participants. It is a randomized clinical trial, meaning participants will be assigned by chance to receive either the active taVNS treatment or a sham (inactive) taVNS treatment.
- What's involved
- Participants will receive either active or sham taVNS delivered via a TENS Device 7000. The study will measure how many people complete 2 weeks of intervention and tolerate each 15-minute session.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be monitored for up to 2 weeks after starting the taVNS treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
At a glance
Conditions
NCT06927024
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
NYU Langone Health
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Qandeel Soomro, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Proportion of Patients who Complete 2 Weeks of InterventionWeek 2
Proportion of patients who use the device for 2 weeks (14 sessions). Measure of feasibility.
- Proportion of Patients who Tolerate Each Full 15-Minute SessionWeek 2
Proportion of patients who use the device for 2 weeks (14 sessions), 15 minutes per session. Measure of feasibility
- Incidence of Severe Bradycardia following taVNS UseUp to Week 2
Severe bradycardia defined as heart rate (HR) \<50 beats per minute. Measure of safety.
- Incidence of Severe Tachycardia following taVNS UseUp to Week 2
Severe tachycardia defined as heart rate (HR) \>100 beats per minute. Measure of safety.
- Incidence of Syncope following taVNS UseUp to Week 2
Measure of safety.